Condition: Nasopharyngeal Carcinoma · Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.
This description comes directly from the study's public registry record.
Xianfeng Zhu · +86 512 6285 8368 · xianfeng.zhu@medilinkthera.com
Xian Zhang · +86 512 6285 8368 · zhangxian@medilinkthera.com
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06629597